ImageneBio Inc
IMA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 1.03 | 4.09 | 2.73 |
| FCF Yield | -38.34% | -0.44% | -1.42% | -0.66% |
| EV / EBITDA | 0.92 | -86.59 | -76.69 | -75.94 |
| Quality | ||||
| ROIC | -17.46% | -7.13% | -8.57% | -9.31% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.08 | 1.24 | 1.23 | 0.69 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -678.55% | 67.60% | -68.72% | 29.96% |
| Safety | ||||
| Net Debt / EBITDA | 3.72 | 6.30 | 3.25 | 2.64 |
| Interest Coverage | -277.02 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -1,024.00 | -19.50 | -17.63 |